VK2735-101 subcutaneous parts A and B
49 evidence topics · 8 sources
Objective
Safety, tolerability, and dose identification as primary objectives
Exploratory pharmacodynamic assessments of body weight and liver fat
First administration to humans and nonalcoholic steatohepatitis as the initial target
Study objectives in the ISRCTN record
Location and study date
Single centre in Adelaide, Australia, in the ISRCTN record
| Field | Registry value |
|---|---|
| Countries of recruitment | “Australia” |
| Study participating centre | “Cmax Clinical Research Pty Ltd” |
| Date of first enrolment | “01/12/2021” |
| Date of final enrolment | “01/06/2023” |
| Planned study period | “December 2021 to December 2022” |
Study dates and site in the ClinicalTrials.gov record (Parts A, B, and C)
| Field | Registry value |
|---|---|
| Study start (actual) | “2021-12-14” |
| Primary completion (actual) | “2024-11-04” |
| Study completion (actual) | “2024-12-03” |
| Site | “Viking Clinical Site” |
| Site city | “Adelaide” |
Results announced in March 2023 and presented at ObesityWeek 2023
Study design
Randomized, double-blind, placebo-controlled single and multiple ascending dose design
Parts A and B and safety review before dose escalation in the ClinicalTrials.gov record
Cohorts and 3:1 randomization in the ISRCTN record
Design details in the ClinicalTrials.gov record
Eligibility criteria
Healthy adults in Part A and adults with a body mass index of at least 30 kg/m2 in Part B
Participants and age range in the ISRCTN record
Key inclusion criteria in the ISRCTN record
Key exclusion criteria in the ISRCTN record
Treatment
Subcutaneous formulation: single ascending doses in Part A
Subcutaneous formulation: once-weekly multiple ascending doses for 4 weeks in Part B
Subcutaneous formulation: weekly dose levels in the multiple ascending dose cohorts
| Cohort | Dose level |
|---|---|
| Cohort 1 | “VK2735 0.5 mg” |
| Cohort 2 | “VK2735 1.5 mg” |
| Cohort 3 | “VK2735 1.5/3/5/5 mg” |
| Cohort 4 | “VK2735 3/5/5/7.5 mg” |
| Cohort 5 | “VK2735 5/5/7.5/10 mg” |
| Escalation in cohort 3 | “Subjects received escalating weekly doses of 1.5 mg, 3.0 mg, 5.0 mg, 5.0 mg.” |
Subcutaneous formulation: arms in the ClinicalTrials.gov record
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Registered primary and secondary outcome measures in ClinicalTrials.gov
Primary and key secondary outcome measures in the ISRCTN record
Statistical analysis description
Number of participants (Planned and analyzed)
Target sample size in the ISRCTN record
Actual enrollment in the ClinicalTrials.gov record (Parts A, B, and C)
| Field | Registry value |
|---|---|
| Enrollment (actual) | “92” |
Description of analysis sets
Statistical methods for liver fat
Results
Participant disposition
No discontinuations for gastrointestinal adverse events in the multiple ascending dose cohorts
Baseline characteristics
Efficacy results
Subcutaneous formulation: pharmacokinetics after single doses
Subcutaneous formulation: pharmacokinetic summary in the corporate presentation
Change in body weight by multiple ascending dose cohort at day 28
| Measure | Placebo (n=10) | 0.5 mg (n=6) | 1.5 mg (n=6) | 1.5/3/5/5 mg (n=7) | 3/5/5/7.5 mg (n=6) | 5/5/7.5/10 mg (n=6) |
|---|---|---|---|---|---|---|
| Mean change from baseline body weight | “-2.2 kg” | “-2.6 kg” | “-4.1 kg” | “-4.5 kg” | “-8.2 kg” | “-7.6 kg” |
| Mean percent change from baseline | “-1.8 %” | “-2.5 %” | “-3.7 %” | “-4.1 %” | “-7.4 %” | “-7.8 %” |
| Placebo-adjusted mean change from baseline | “-” | “-0.7 %” | “-1.9 %” | “-2.3 %” | “-5.6 %” | “-6.0 %” |
| p-value vs. placebo | “-” | “0.64” | “0.17” | “0.09” | “0.0003” | “0.0002” |
Durability of weight loss after the last dose
Conclusions of the ObesityWeek 2023 abstract
Liver fat after 28 days of weekly dosing
Change in liver fat content by multiple ascending dose cohort
| Measure | Placebo | 0.5 mg | 1.5 mg | 1.5/3/5/5 mg | 3/5/5/7.5 mg | 5/5/7.5/10 mg |
|---|---|---|---|---|---|---|
| Mean percent change from baseline, all participants | “-0.7” | “3.9” | “-24.2” | “-24.0” | “-47.2” | “-8.4” |
| p-value vs. placebo, all participants | “-” | “0.74” | “0.09” | “0.10” | “0.002” | “0.62” |
| Mean percent change from baseline, nonalcoholic fatty liver disease subset | “8.8” | “-” | “-33.8” | “-32.5” | “-49.7” | “-10.7” |
| p-value vs. placebo, nonalcoholic fatty liver disease subset | “-” | “-” | “0.03” | “0.03” | “0.006” | “-” |
Plasma lipids after 28 days of weekly dosing
Change in plasma lipids by multiple ascending dose cohort
| Measure | Placebo (n=9) | 0.5 mg (n=6) | 1.5 mg (n=6) | 1.5/3/5/5 mg (n=6) | 3/5/5/7.5 mg (n=6) | 5/5/7.5/10 mg (n=4) |
|---|---|---|---|---|---|---|
| Mean change in apolipoprotein B from baseline (%) | “1.8” | “3.3” | “-1.8” | “-12.9” | “-12.5*” | “-20.5” |
| Mean change in LDL-C from baseline (%) | “-9.5” | “1.4” | “-10.6” | “-13.7” | “-20.3*” | “-23.0” |
| Mean change in total cholesterol from baseline (%) | “-5.1” | “-1.7” | “-10.8” | “-14.9*” | “-17.4*” | “-21.0” |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Tolerability of single doses
Adverse events after repeated weekly dosing
Commonly reported adverse events by multiple ascending dose cohort
| Event | Placebo (n=10) | 0.5 mg (n=6) | 1.5 mg (n=6) | 1.5/3/5/5 mg (n=7) | 3/5/5/7.5 mg (n=6) | 5/5/7.5/10 mg (n=6) |
|---|---|---|---|---|---|---|
| Nausea, mild | “5 (50%)” | “2 (33%)” | “4 (67%)” | “4 (57%)” | “5 (83%)” | “1 (17%)” |
| Nausea, moderate | “0 (0%)” | “0 (0%)” | “0 (0%)” | “1 (14%)” | “0 (0%)” | “1 (17%)” |
| Vomiting | “1 (10 %)” | “2 (33 %)” | “0 (0 %)” | “2 (29 %)” | “1 (17 %)” | “1 (17 %)” |
| Diarrhea | “3 (30 %)” | “1 (17 %)” | “1 (17 %)” | “2 (29 %)” | “0 (0 %)” | “0 (0 %)” |
| Constipation | “0 (0 %)” | “1 (17 %)” | “1 (17 %)” | “2 (29 %)” | “1 (17 %)” | “0 (0 %)” |
| Decreased appetite | “3 (30 %)” | “3 (50 %)” | “3 (50 %)” | “4 (57 %)” | “5 (83 %)” | “6 (100 %)” |
Higher doses expected to need longer titration
Study limitations
Summary: study limitations
VK2735-101 Parts A and B were the first administration of VK2735 to humans, conducted at a single centre in Adelaide, Australia, in healthy adults (Part A) and otherwise healthy adults with a body mass index of at least 30 kg/m2 (Part B). The registered primary endpoint was the incidence of treatment-emergent adverse events, and body weight, liver fat, and lipids were exploratory pharmacodynamic measures. The multiple ascending dose part dosed participants once weekly for 4 weeks, with 6 or 7 participants in each VK2735 cohort and 10 receiving placebo, and the highest weekly dose (10 mg) is lower than the doses later carried into phase 2 and phase 3. The liver fat subgroup with nonalcoholic fatty liver disease contained 0 to 4 participants per cohort. Single-dose results by dose level, participant disposition, and baseline characteristics other than body weight and liver fat were not reported. The ISRCTN record named nonalcoholic steatohepatitis as the condition VK2735 was being developed for and a target sample size of 88; the ClinicalTrials.gov record reports an actual enrollment of 92 for Parts A, B, and C combined, whereas the oral first-in-human poster reports that 92 participants were randomized in the oral part alone. The two documents also differ on the time to maximum concentration (approximately 75 to 90 hours in the results release and about 72 hours in the corporate presentation). Results are available only in press releases, a corporate presentation, and a congress abstract, with no peer-reviewed full publication and no results posted to either registry.